Hydroxychloroquine for COVID19 : The curtains close on a comedy of errors - The Lancet Regional Health – Americas
►https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00085-0/fulltext
(bref) article, entièrement accessible
Early in the COVID-19 pandemic, there was a desperate need for a therapy against the scourge which was decimating health care systems worldwide. As systems became overwhelmed, it was clear that effective, safe, accessible early outpatient treatments to prevent deterioration were needed. Scientists turned first to therapies that had shown anecdotal promise or in vitro activity against SARS. In many respects, hydroxychloroquine, an off-patent antimalarial used for autoimmune diseases, with decades of safety data, and with data suggesting in vitro efficacy in SARS-Cov-1, was an ideal candidate therapy.1 What happened next, however, was an unfortunate comedy of errors which squandered resources and opportunities to find effective therapies.
[…]
With dozens of trials now published, we can finally close the curtains on hydroxychloroquine for COVID-19. However, we would be remiss if we did not draw some lessons for future pandemics and for clinical science in general.
…
suivent trois leçons à tirer pour l’avenir que je vous laisse découvrir
pas sûr que ce soit gagné…